About this trial
The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their short-term (in-hospital) and medium-term (12-month) prognosis. Extending the follow-up beyond 12 months for this first study would provide fundamental data for understanding and improving the care of these patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
314 women who had a myocardial infarction at less than 50 years, included in the WAMIF study conducted from 2017 to 2019 in 30 French research centers.
Trial design
Cohort
Prospective
Treatments tested in this trial
Questionnaires
Other interventionAssessment of stress and anxiety and quality of life after myocardial infarct: * Stress score: Perceived Stress Scale-4 (PSS-4) * Anxiety score: Generalized Anxiety Disorder-7 (GAD-7) * Depression score: Patient Health Questionnaire-9 (PHQ-9) * Quality of life scores: European Quality of Life-5 Dimensions (EQ-5D) and 12-Item Short-Form General Health Survey (SF-12)
Major events
Other interventionCollection of information related to major events occurring since inclusion in the WAMIF study
Treatment groups
Trial outcomes
Primary outcomes
Death from any cause
Number of patient who died from any cause since their participation in WAMIF study
Cardiovascular death
Number of patient who died from cardiovascular cause since their participation in WAMIF study
Stent thrombosis
Number of patient who had stent thrombosis since their participation in WAMIF study
Stroke
Number of patient who had stroke since their participation in WAMIF study
Secondary outcomes
Stress score
Perceived Stress Scale 4 items. It provides a total score (range 10-50, from worst to best) to assess the state of stress perceived by the patient
Anxiety score
Generalized Anxiety Disorder 7 items. It provides a total score to evaluate patient anxiety (range 0 to 21: 0-4: minimal anxiety; 5-9: mild anxiety; 10-14: moderate anxiety; 15-21: severe anxiety)
Depression score
Patient Health Questionnaire 9 items. It provides a total score (range 0-27, 1-4 minimal depression; 5-9 mild depression; 10-14 moderate depression; 15-19 moderately severe depression; 20-27 severe depression) to diagnose and measure severity of depression.
Quality of life score
European Quality of Life 5 Dimensions. It provides a total score (range 0-100, from worst to the best) to evaluate the generic quality of life
Sponsors and contacts
Click on the lead sponsor to view all of their trials.